Home / news / The Weekly Investment Analysts’ Ratings Updates for Vertex Pharmaceuticals (VRTX)

The Weekly Investment Analysts’ Ratings Updates for Vertex Pharmaceuticals (VRTX)

collected by :Molly Tony

A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 89.67 on Wednesday.
Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $103.73.
On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post $1.62 earnings per share for the current fiscal year.
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases.
Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%.

as informed in

Vertex Pharmaceuticals (VRTX) Stock: Gains Big On Cystic Fibrosis Study Data

VRTX Releases Positive Clinical Data From Cystic Fibrosis StudiesAs mentioned above, Vertex Pharmaceuticals is having an incredibly strong day in the market today, and for good reason.
The company has announced the success of two clinical trials surrounding tezacaftor as a treatment for the underlying cause of cystic fibrosis.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Vertex Pharmaceuticals is having an overwhelmingly strong start to the day in the pre-market hours after announcing positive clinical trial data.
The study showed that through the course of 24 weeks, when combining tezacaftor with ivacaftor, an already approved drug by VRTX, patients saw improved lung function by 4%.
Currently (9:02), VRTX is trading at $108.29 per share after a gain of $18.62 per share or 20.77% thus far today.

Trading Insight: Taking a Look at Levels for Vertex Pharmaceuticals Inc (VRTX)

as informed in The ADX is typically plotted along with two other directional movement indicator lines, the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI).
An RSI reading over 70 would be considered overbought, and a reading under 30 would indicate oversold conditions.
Traders may be relying in part on technical stock analysis.
A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction.
Vertex Pharmaceuticals Inc (VRTX) currently has a 50-day Moving Average of 88.77, the 200-day Moving Average is 87.7, and the 7-day is noted at 92.71.

read more
visit us
Markets

Check Also

cheap stocks

Cheap stocks and its trading in financial markets

Cheap stocks, also known as Cent stocks, are ordinary shares of small public companies traded …